56131-46-5

Basic information

• Product Name: 3-bromo-2-chloroaniline
• Synonyms: 3-Bromo-2-chloroaniline 95%;Benzenamine, 3-bromo-2-chloro-;3-bromo-2-chloroaniline ISO 9001：2015 REACH
• CAS NO: 56131-46-5
• Molecular Formula: C₆H₅BrClN
• Molecular Weight: 206.4676
• Mol File: 56131-46-5.mol
• Article Data: 11

Chemical Properties

• Melting Point: 31-33 °C
• Boiling Point: 267.1±20.0 °C(Predicted)
• Appearance: /
• Density: 1.722±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 1.58±0.10(Predicted)
• CAS DataBase Reference: 3-bromo-2-chloroaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 3-bromo-2-chloroaniline(56131-46-5)
• EPA Substance Registry System: 3-bromo-2-chloroaniline(56131-46-5)

Safety Data

• RIDADR: UN2019
• Hazardous Substances Data: 56131-46-5(Hazardous Substances Data)

Usage

General Description

3-bromo-2-chloroaniline is a chemical compound with the molecular formula C6H5BrClN. It is a halogen-substituted aniline, which is an aromatic amine commonly used in the production of dyes, pharmaceuticals, and agrochemicals. The presence of both bromine and chlorine atoms on the aniline ring makes 3-bromo-2-chloroaniline an important intermediate in organic synthesis, as well as a useful building block for creating more complex molecules. It is also known to have potential applications in the field of medicinal chemistry due to its unique chemical structure and reactivity. However, it is important to handle 3-bromo-2-chloroaniline with caution as it is a potentially hazardous chemical and should be used and stored according to proper safety protocols.

Upstream product

• 121-18-6 3-nitro-4-chlorobenzenesulfonic acid 
• 59255-95-7 2-bromo-6-nitroaniline 
• 58534-94-4 2-fluoro-3-bromonitrobenzene 
• 863870-87-5 3 -bromo-2-chlorophenol 
• 1287791-79-0 N-(3-bromo-2-chlorophenyl)-2-hydroxy-2-methylpropanamide 
• 1287791-70-1 2-(3-bromo-2-chlorophenoxy)-2-methylpropanamide 
• 863870-81-9 O-3-bromo-2-chlorophenyl N,N-diethylcarbamate 
• 863870-72-8 O-3-bromophenyl N,N-diethylcarbamate 
• 3970-37-4 1-bromo-2-chloro-3-nitrobenzene 

Downstream Products

• 905438-50-8 3-bromo-2-chloro-N-cyclopropylaniline hydrochloride 
• 1269233-01-3 2-chloro-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)phenylamine 
• 1269233-02-4 N-(3-bromo-2-chlorophenyl)propane-1-sulfonamide 

Relevant articles and documents

Preparation method 2 - chloro -3 - bromoaniline

The invention discloses a preparation method of 2 - chloro -3 - bromoaniline, and the specific steps of the preparation method are as follows: (1) the compound II and the bromosuccinimide are subjected to electrophilic substitution reaction to generate the compound III. (2) The sulfonic acid group of the compound III was removed to give compound IV. (3) Compound IV is reduced to compound I with a safety powder, i.e. said 2 - chloro -3 - bromoaniline. To the invention, 4 - chlorine -3 - nitrobenzene sulfonic acid is used as a starting raw material in a full synthetic route process, reagents with large toxicity and large pollution are avoided, and meanwhile, the raw materials are low in price and higher in yield.

COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF

Disclosed are a class of coumarin-like cyclic compounds as MEK inhibitors and pharmaceutical compositions comprising the compounds, and the use of same in the preparation of a drug for treating MEK-related diseases. Particularly disclosed are compounds as shown in formula (I) and pharmaceutically acceptable salts thereof or tautomers thereof.

SUBSTITUTED QUINAZOLINE COMPOUNDS AND THEIR USE AS INHIBITORS OF G12C MUTANT KRAS, HRAS AND/OR NRAS PROTEINS

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R, R1, R2a, R2b, R2c, A, B, L1 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.